This study is looking at how safe and effective a medicine called pegozafermin is for people with a liver disease named compensated cirrhosis due to MASH. MASH stands for "Metabolic Associated Steatohepatitis," which is a liver problem linked to fat build-up and inflammation. In this study, you must be between 18 and 75 years old, have a liver biopsy showing a certain level of scarring (stage F4), and have a body mass index (BMI) that fits the requirements. You should not have other liver diseases or cancer, and your diabetes should be well controlled. This study will help find out if pegozafermin can help and if it is safe. Here's what you need to know:

• The study involves taking the medicine and regular check-ups to see how it works.
• Participants must have certain health conditions but shouldn't have others like severe diabetes.
• It's important to discuss with your doctor if joining this study is right for you.